Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.
The enterprise value of the monster deal was estimated at almost $49 billion.
Kimberly-Clark completed the acquisition of Kenvue, a consumer healthcare company, in a deal valued at approximately $48.7 billion. The merger combines two prominent American companies, offering a portfolio of complementary products and reaching nearly half the global population. Kimberly-Clark, known for Kleenex and Huggies, will become a leading player in health and hygiene products, including Tylenol, Johnson's Baby, and Listerine.
The deal involved a mix of cash and stock, with Kenvue investors receiving $3.50 per share in cash and nearly 0.15 of a Kimberly-Clark share for each Kenvue share. Kimberly-Clark aims to achieve $2.1 billion in annual synergies within three years of the acquisition, along with incremental dividend raises to maintain its Dividend King status, which has been intact for 54 years.
While the financing commitments are significant, Kimberly-Clark is expected to continue its dividend increases and may restore share repurchases in the future.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
